Pravastatin reduces marfan aortic dilation

Darren McLoughlin, Jonathan McGuinness, John Byrne, Eloisa Terzo, Vilhelmiina Huuskonen, Hester McAllister, Alexander Black, Sinead Kearney, Elaine Kay, Arnold D K Hill, Harry C Dietz, J. Mark Redmond

Research output: Contribution to journalArticle

Abstract

Background-The sequelae of aortic root dilation are the lethal consequences of Marfan syndrome. The root dilation is attributable to an imbalance between deposition of matrix elements and metalloproteinases in the aortic medial layer as a result of excessive transforming growth factor-beta signaling. This study examined the efficacy and mechanism of statins in attenuating aortic root dilation in Marfan syndrome and compared effects to the other main proposed preventative agent, losartan. Methods and Results-Marfan mice heterozygous for a mutant allele encoding a cysteine substitution in fibrillin-1 (C1039G) were treated daily from 6 weeks old with pravastatin 0.5g/L or losartan 0.6 g/L. The end points of aortic root diameter (n=25), aortic thickness, and architecture (n=10), elastin volume (n=5), dp/dtmax (maximal rate of change of pressure) (cardiac catheter; n=20), and ultrastructural analysis with stereology (electron microscopy; n=5) were examined. The aortic root diameters of untreated Marfan mice were significantly increased in comparison to normal mice (0.161±0.001 cm vs 0.252±0.004 cm; P

Original languageEnglish (US)
JournalCirculation
Volume124
Issue number11 SUPPL. 1
DOIs
StatePublished - Sep 13 2011

Fingerprint

Pravastatin
Dilatation
Marfan Syndrome
Losartan
Cardiac Catheters
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Elastin
Matrix Metalloproteinases
Transforming Growth Factor beta
Cysteine
Electron Microscopy
Alleles
Pressure

Keywords

  • aneurysm
  • aorta
  • pathology
  • remodeling
  • vessels

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

McLoughlin, D., McGuinness, J., Byrne, J., Terzo, E., Huuskonen, V., McAllister, H., ... Redmond, J. M. (2011). Pravastatin reduces marfan aortic dilation. Circulation, 124(11 SUPPL. 1). https://doi.org/10.1161/CIRCULATIONAHA.110.012187

Pravastatin reduces marfan aortic dilation. / McLoughlin, Darren; McGuinness, Jonathan; Byrne, John; Terzo, Eloisa; Huuskonen, Vilhelmiina; McAllister, Hester; Black, Alexander; Kearney, Sinead; Kay, Elaine; Hill, Arnold D K; Dietz, Harry C; Redmond, J. Mark.

In: Circulation, Vol. 124, No. 11 SUPPL. 1, 13.09.2011.

Research output: Contribution to journalArticle

McLoughlin, D, McGuinness, J, Byrne, J, Terzo, E, Huuskonen, V, McAllister, H, Black, A, Kearney, S, Kay, E, Hill, ADK, Dietz, HC & Redmond, JM 2011, 'Pravastatin reduces marfan aortic dilation', Circulation, vol. 124, no. 11 SUPPL. 1. https://doi.org/10.1161/CIRCULATIONAHA.110.012187
McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H et al. Pravastatin reduces marfan aortic dilation. Circulation. 2011 Sep 13;124(11 SUPPL. 1). https://doi.org/10.1161/CIRCULATIONAHA.110.012187
McLoughlin, Darren ; McGuinness, Jonathan ; Byrne, John ; Terzo, Eloisa ; Huuskonen, Vilhelmiina ; McAllister, Hester ; Black, Alexander ; Kearney, Sinead ; Kay, Elaine ; Hill, Arnold D K ; Dietz, Harry C ; Redmond, J. Mark. / Pravastatin reduces marfan aortic dilation. In: Circulation. 2011 ; Vol. 124, No. 11 SUPPL. 1.
@article{4a114ccff43e43f19d98b4c35ea19518,
title = "Pravastatin reduces marfan aortic dilation",
abstract = "Background-The sequelae of aortic root dilation are the lethal consequences of Marfan syndrome. The root dilation is attributable to an imbalance between deposition of matrix elements and metalloproteinases in the aortic medial layer as a result of excessive transforming growth factor-beta signaling. This study examined the efficacy and mechanism of statins in attenuating aortic root dilation in Marfan syndrome and compared effects to the other main proposed preventative agent, losartan. Methods and Results-Marfan mice heterozygous for a mutant allele encoding a cysteine substitution in fibrillin-1 (C1039G) were treated daily from 6 weeks old with pravastatin 0.5g/L or losartan 0.6 g/L. The end points of aortic root diameter (n=25), aortic thickness, and architecture (n=10), elastin volume (n=5), dp/dtmax (maximal rate of change of pressure) (cardiac catheter; n=20), and ultrastructural analysis with stereology (electron microscopy; n=5) were examined. The aortic root diameters of untreated Marfan mice were significantly increased in comparison to normal mice (0.161±0.001 cm vs 0.252±0.004 cm; P",
keywords = "aneurysm, aorta, pathology, remodeling, vessels",
author = "Darren McLoughlin and Jonathan McGuinness and John Byrne and Eloisa Terzo and Vilhelmiina Huuskonen and Hester McAllister and Alexander Black and Sinead Kearney and Elaine Kay and Hill, {Arnold D K} and Dietz, {Harry C} and Redmond, {J. Mark}",
year = "2011",
month = "9",
day = "13",
doi = "10.1161/CIRCULATIONAHA.110.012187",
language = "English (US)",
volume = "124",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11 SUPPL. 1",

}

TY - JOUR

T1 - Pravastatin reduces marfan aortic dilation

AU - McLoughlin, Darren

AU - McGuinness, Jonathan

AU - Byrne, John

AU - Terzo, Eloisa

AU - Huuskonen, Vilhelmiina

AU - McAllister, Hester

AU - Black, Alexander

AU - Kearney, Sinead

AU - Kay, Elaine

AU - Hill, Arnold D K

AU - Dietz, Harry C

AU - Redmond, J. Mark

PY - 2011/9/13

Y1 - 2011/9/13

N2 - Background-The sequelae of aortic root dilation are the lethal consequences of Marfan syndrome. The root dilation is attributable to an imbalance between deposition of matrix elements and metalloproteinases in the aortic medial layer as a result of excessive transforming growth factor-beta signaling. This study examined the efficacy and mechanism of statins in attenuating aortic root dilation in Marfan syndrome and compared effects to the other main proposed preventative agent, losartan. Methods and Results-Marfan mice heterozygous for a mutant allele encoding a cysteine substitution in fibrillin-1 (C1039G) were treated daily from 6 weeks old with pravastatin 0.5g/L or losartan 0.6 g/L. The end points of aortic root diameter (n=25), aortic thickness, and architecture (n=10), elastin volume (n=5), dp/dtmax (maximal rate of change of pressure) (cardiac catheter; n=20), and ultrastructural analysis with stereology (electron microscopy; n=5) were examined. The aortic root diameters of untreated Marfan mice were significantly increased in comparison to normal mice (0.161±0.001 cm vs 0.252±0.004 cm; P

AB - Background-The sequelae of aortic root dilation are the lethal consequences of Marfan syndrome. The root dilation is attributable to an imbalance between deposition of matrix elements and metalloproteinases in the aortic medial layer as a result of excessive transforming growth factor-beta signaling. This study examined the efficacy and mechanism of statins in attenuating aortic root dilation in Marfan syndrome and compared effects to the other main proposed preventative agent, losartan. Methods and Results-Marfan mice heterozygous for a mutant allele encoding a cysteine substitution in fibrillin-1 (C1039G) were treated daily from 6 weeks old with pravastatin 0.5g/L or losartan 0.6 g/L. The end points of aortic root diameter (n=25), aortic thickness, and architecture (n=10), elastin volume (n=5), dp/dtmax (maximal rate of change of pressure) (cardiac catheter; n=20), and ultrastructural analysis with stereology (electron microscopy; n=5) were examined. The aortic root diameters of untreated Marfan mice were significantly increased in comparison to normal mice (0.161±0.001 cm vs 0.252±0.004 cm; P

KW - aneurysm

KW - aorta

KW - pathology

KW - remodeling

KW - vessels

UR - http://www.scopus.com/inward/record.url?scp=80052719936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052719936&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.110.012187

DO - 10.1161/CIRCULATIONAHA.110.012187

M3 - Article

C2 - 21911808

AN - SCOPUS:80052719936

VL - 124

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11 SUPPL. 1

ER -